Skip to main content

Advertisement

Table 5 Genotype and allele frequency distributions among patients with or without neuropsychiatric disorders during efavirenz based HAART

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Genotype Neuropsychiatric disorders p value
  No   Yes
n % n %
CYP2B6*6 *1/*1 21 42 61 44.5 0.16
*1/*6 28 56 63 46  
*6/*6 1 2 13 9.5  
CYP2B6*11 *1/*1 41 82 111 78.2 0.17
*1/*11 8 16 31 21.8  
*11/*11 1 2 0 0  
CYP2A6*9 *1/*1 39 84.8 98 79.7 0.51
*1/*9 7 15.2 22 17.9  
*9/*9 0 0 3 2.4  
CYP2A6*17 *1/*1 38 90.5 104 83.9 0.3
*1/*17 3 7.1 19 15.3  
*17/*17 1 2.4 1 0.8  
No. of CYP3A5*1 allelesa zero 15 30 31 21.8 0.48
One 24 48 79 55.6  
Two 11 22 32 22.5  
ABCB1 (rs3842 *0/*0 29 63 87 65.4 0.95
*0/*1 16 34.8 43 32.3  
*1/*1 1 2.2 3 2.3  
ABCB1 c.3435C/T CC 37 74 109 77.9 0.68
CT 13 26 30 21.4  
TT 0 0 1 0.7  
NR1I3 rs3003569CT TT 10 21.7 29 23 0.06
TC 16 34.8 65 51.6  
CC 20 43.5 32 25.4  
Alleles Frequency (%) Frequency (%)  
CYP2B6*6 30 32.5 0.21
CYP2B6*11 10 10.9 0.78
CYP2A6*9 7.61 11.38 0.31
CYP2A6*17 5.95 8.46 0.55
No. of CYP3A5*1 allele 46 50.4 0.56
ABCB1 rs3842 19.6 18.4 0.80
ABCB1 c.3435T 13 11.4 0.67
NR1I3 rs3003569 T 39.1 48.8 0.11
  1. P value from binary logistic regression is presented.
  2. a Haplotype analyses indicate no linkage between CYP3A5 SNPs thus subjects were grouped based on number of functional CYP3A5 allele (CYP3A5*1) for statistical analysis.